Drugs affecting blood pressure variability: An Update

Current Pharmaceutical Design

Volumn 21, Issue 6, 2015, Pages 744-755

  Höcht, Christian ^a,b   Del Mauro, Julieta Sofía ^a   Bertera, Facundo Martín ^a,b   Taira, Carlos Alberto ^a,b  

^a Department of Pharmacology ^*  (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Blood pressure variability; Calcium channel blockers; Diabetes; Hypertension; Visit to visit variability

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ARTICLE; BEAT TO BEAT BLOOD PRESSURE VARIABLE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CLINICAL STUDY; COMPARATIVE EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HUMAN; HYPERTENSION; LONG TERM CARE; PRIORITY JOURNAL; PROPHYLAXIS; SHORT COURSE THERAPY; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG EFFECTS;

BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CIRCADIAN RHYTHM; HUMANS;

EID: 84925872704     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141024125325     Document Type: Article

References (105)

1. Parati G, Faini A, Valentini M. Blood pressure variability: its measurement and significance in hypertension. Curr Hypertens Rep 2006; 8: 199-204.
2. Grassi G, Bombelli M, Brambilla G, Trevano FQ, Dell'oro R, Mancia G. Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications. Curr Hypertens Rep 2012; 14: 333-8.
3. Su DF, Miao CY. Reduction of blood pressure variability: a new strategy for the treatment of hypertension. Trends Pharmacol Sci 2005; 26: 388-90.
4. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10: 143-55.
5. Parati G, Ochoa JE, Salvi P, Lombardi C, Bilo G. Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes. Diabetes Care 2013; 36 (Suppl 2): S312-24.
6. Stauss HM. Identification of blood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol 2007; 34: 362-8.
7. Floras JS. Blood pressure variability: a novel and important risk factor. Can J Cardiol 2013; 29: 557-63.
8. Höcht C. Blood Pressure Variability: Prognostic Value and Therapeutic Implications. ISRN Hypertension 2013; Article ID 398485.
9. Shimbo D, Shea S, McClelland RL, et al. Associations of aortic distensibility and arterial elasticity with long-term visit-to-visit blood pressure variability: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens 2013; 26: 896-902.
10. Kikuya M, Ohkubo T, Metoki H, et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension 2008; 52: 1045-50.
11. Chowdhury EK, Owen A, Krum H, Wing LM, Nelson MR, Reid CM. Systolic blood pressure variability is an important predictor of cardiovascular outcomes in elderly hypertensive patients. J Hypertens 2014; 32: 525-33.
12. Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes. J Diabetes Complications 2014; 28: 185-90.
13. Kostis JB, Sedjro JE, Cabrera J, et al. Visit-to-Visit Blood Pressure Variability and Cardiovascular Death in the Systolic Hypertension in the Elderly Program. J Clin Hypertens 2014; 16: 34-40.
14. Parati G, Liu X, Ochoa JE. Clinical relevance of visit-to-visit blood pressure variability: impact on renal outcomes. J Hum Hypertens 2013; in press.
15. Noshad S, Mousavizadeh M, Mozafari M, Nakhjavani M, Esteghamati A. Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes. J Hum Hypertens 2014; 28: 37-43.
16. Choi HJ. Blood pressure variability and its management in hypertensive patients. Korean J Fam Med 2012; 33: 330-5.
17. Schillaci G, Pucci G, Parati G. Blood pressure variability: an additional target for antihypertensive treatment? Hypertension 2011; 58: 133-5.
18. Langager AM, Hammerberg BE, Rotella DL, Stauss HM. Very low-frequency blood pressure variability depends on voltage-gated L-type Ca2+ channels in conscious rats. Am J Physiol Heart Circ Physiol 2007; 292: H1321-7.
19. Souza HC, Martins-Pinge MC, Dias da Silva VJ, et al. Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton Neurosci 2008; 139: 38-45.
20. Fazan R Jr, Huber DA, Silva CA, Dias da Silva VJ, Salgado MC, Salgado HC. Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 2008; 104: 1683-9.
21. Janssen BJ, Oosting J, Slaaf DW, Persson PB, Struijker-Boudier HA. Hemodynamic basis of oscillations in systemic arterial pressure in conscious rats. Am J Physiol 1995; 269: H62-71.
22. Bertera FM, Del Mauro JS, Chiappetta D, et al. Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 325-35.
23. Bertera FM, Del Mauro JS, Lovera V, et al. Acute effects of third generation_-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats. Hypertens Res 2013; 36: 349-55.
24. Just A, Faulhaber J, Ehmke H. Autonomic cardiovascular control in conscious mice. Am J Physiol Regul Integr Comp Physiol 2000; 279: R2214-21.
25. Dantas EM, Pimentel EB, Andreão RV, Cichoni BS, Gonçalves CP, Zaniqueli Ddos A, Baldo MP, Rodrigues SL, Mill JG. Carvedilol recovers normal blood pressure variability in rats with myocardial infarction. Auton Neurosci 2013; 177: 231-6.
26. Ponchon P, Elghozi JL. Contribution of the renin-angiotensin and kallikrein-kinin systems to short-term variability of blood pressure in two-kidney, one-clip hypertensive rats. Eur J Pharmacol 1996; 297: 61-70.
27. Nobre F, da Silva CA, Coelho EB, Salgado HC, Fazan R Jr. Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats. Am J Hypertens 2006; 19: 1079-83.
28. Parati G, Saul JP, Di Rienzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. A critical appraisal. Hypertension 1995; 25: 1276-86.
29. Parati G, Castiglioni P, Di Rienzo M, et al. Sequential spectral analysis of 24-hour blood pressure and pulse interval in humans. Hypertension 1990; 16: 414-21.
30. Omboni S, Parati G, Castiglioni P, et al. Estimation of blood pressure variability from 24-hour ambulatory finger blood pressure. Hypertension 1998; 32: 52-8.
31. Frattola A, Parati G, Castiglioni P, et al. Lacidipine and blood pressure variability in diabetic hypertensive patients. Hypertension 2000; 36: 622-8.
32. Hermida RC, Ayala DE, Fernández JR, et al. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int 2013; 30: 280-314.
33. Hermida RC, Ayala DE, Chayan L, Mojon A, Fernandez JR. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int 2009; 26: 61-79.
34. Tofé Povedano S, García De La Villa B. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens 2009; 11: 426-31.
35. Fukuda M, Yamanaka T, Mizuno M, Motokawa M, Shirasawa Y, Miyagi S, Nishio T, Yoshida A, Kimura G. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing day-time natriuresis. J Hypertens 2008; 26: 583-8.
36. Hermida RC, Ayala DE, Fernández JR, Calvo C. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 2007; 50: 715-22.
37. Hermida RC, Ayala DE. Chronotherapy with the angiotensinconverting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 2009; 54: 40-6.
38. Meng Y, Zhang Z, Liang X, Wu C, Qi G. Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension. Acta Cardiol 2010; 65: 309-14.
39. Zeng J, Jia M, Ran H, et al. Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study. Hypertens Res 2011; 34: 767-72.
40. Hermida RC, Ayala DE, Mojón A, Fernández JR. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am J Hypertens. 2008; 21: 948-54.
41. Hoshino A, Nakamura T, Matsubara H. The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. Clin Exp Hypertens 2010; 32: 416-22.
42. Koga H, Hayashi J, Yamamoto M, Kitamoto K. Prevention of morning surge of hypertension by the evening administration of carvedilol. J Med Assoc J 2005; 48: 398-403.
43. Acelajado MC, Pisoni R, Dudenbostel T, Oparil S, Calhoun DA, Glasser SP. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens 2012; 6: 66-72.
44. Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010; 27: 1629-51.
45. Halberg F, Powell D, Otsuka K, et al. Diagnosing vascular variability anomalies, not only MESOR-hypertension. Am J Physiol Heart Circ Physiol 2013; 305: H279-94.
46. Otsuka K, Cornélissen G, Halberg F, Oehlerts G. Excessive circadian amplitude of blood pressure increases risk of ischaemic stroke and nephropathy. J Med Eng Technol 1997; 21: 23-30.
47. Shinagawa M, Kubo Y, Otsuka K, et al. Impact of circadian amplitude and chronotherapy: relevance to prevention and treatment of stroke. Biomed Pharmacother 2001; 55 (Suppl 1): 125s-132s.
48. Watanabe Y, Cornélissen G, Watanabe M, et al. Effects of autogenic training and antihypertensive agents on circadian and circaseptan variation of blood pressure. Clin Exp Hypertens 2003; 25: 405-12.
49. Parati G, Lantelme P. Blood pressure variability, target organ damage and cardiovascular events. J Hypertens 2002; 20: 1725-9.
50. Wang J, Shen FM, Wang MW, Su DF. Effects of nine antihypertensive drugs on blood pressure variability in sinoaortic-denervated rats. Acta Pharmacol Sin 2006; 27: 1013-7.
51. Shen FM, Wang J, Ni CR, Yu JG, Wang WZ, Su DF. Ketanserininduced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors. Clin Exp Pharmacol Physiol 2007; 34: 702-7.
52. Han P, Chu ZX, Shen FM, Xie HH, Su DF. Synergism of hydrochlorothiazide and nitrendipine on reduction of blood pressure and blood pressure variability in spontaneously hypertensive rats. Acta Pharmacol Sin 2006; 27: 1575-9.
53. Xu LP, Shen FM, Shu H, Miao CY, Jiang YY, Su DF. Synergism of atenolol and amlodipine on lowering and stabilizing blood pressure in spontaneously hypertensive rats. Fundam Clin Pharmacol 2004; 18: 33-8.
54. Bertera FM, Del Mauro JS, Polizio AH, Chiappetta D, Taira CA, Höcht C. Effect of nebivolol on beat-to-beat and short-term blood pressure variability in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 833-43.
55. Bertera F, Di Verniero CA, Mayer MA, et al. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats. Xenobiotica 2012; 42: 206-19.
56. Bertera FM, Del Mauro JS, Lovera V, et al. Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats. Hypertens Res 2014; 37: 194-201.
57. Di Verniero CA, Bertera F, Buontempo F, et al. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a Nnitro-l-arginine methyl ester rat model of secondary hypertension. J Pharm Pharmacol 2010; 62: 890-900.
58. Kai H, Kudo H, Takayama N, Yasuoka S, Kajimoto H, Imaizumi T. Large blood pressure variability and hypertensive cardiac remodeling--role of cardiac inflammation. Circ J 2009; 73: 2198-203.
59. Kudo H, Kai H, Kajimoto H, et al. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension 2009; 54: 832-8.
60. Tao X, Zhang YJ, Shen FM, Guan YF, Su DF. Fosinopril prevents the pulmonary arterial remodeling in sinoaortic-denervated rats by regulating phosphodiesterase. J Cardiovasc Pharmacol 2008; 51: 24-31.
61. Miao CY, Xie HH, Wang JJ, Su DF. Candesartan inhibits sinoaortic denervation-induced cardiovascular hypertrophy in rats. Acta Pharmacol Sin 2002; 23: 713-20.
62. Shang W, Han P, Yang CB, et al. Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats. Acta Pharmacol Sin 2011; 32: 1109-15.
63. Xie HH, Shen FM, Zhang XF, Jiang YY, Su DF. Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs. Eur J Pharmacol 2006; 543: 77-82.
64. Du WM, Miao CY, Liu JG, Shen FM, Yang XQ, Su DF. Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003; 41: 233-9.
65. Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 2003; 21: 1961-7.
66. Xie HH, Miao CY, Liu JG, Su DF. Importance of blood pressure variability in organ protection in spontaneously hypertensive rats treated with combination of nitrendipine and atenolol. Acta Pharmacol Sin 2002; 23: 1199-204.
67. Xie HH, Zhang XF, Chen YY, Shen FM, Su DF. Synergism of hydrochlorothiazide and nifedipine on blood pressure variability reduction and organ protection in spontaneously hypertensive rats. Hypertens Res 2008; 31: 685-91.
68. Shang W, Han P, Yang CB, Gu XW, Zhang W, Xu LP, Fu ST, Su DF, Xie HH. Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats. Acta Pharmacol Sin 2011; 32: 1109-15.
69. Pierdomenico SD, Di Nicola M, Esposito AL, et al. Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens 2009; 22: 842-7.
70. Mena L, Pintos S, Queipo NV, Aizpúrua JA, Maestre G, Sulbarán T. A reliable index for the prognostic significance of blood pressure variability. J Hypertens 2005; 23: 505-11.
71. Mitsuhashi H, Tamura K, Yamauchi J, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascu lar remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009; 207: 186-90.
72. Masuda S, Tamura K, Wakui H, et al. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res 2009; 32: 950-5.
73. Shigenaga A, Tamura K, Dejima T, et al. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract 2009; 112: c31-40.
74. Crippa G, Venturi C, Carrara G. Effect of antihypertensive treatment with carvedilol or lercanidipine on ambulatory blood pressure variability. Am J Hypertens 2002; 15: 50A.
75. Zakopoulos N, Stamatelopoulos S, Moulopoulos S. Effect of hypotensive drugs on the circadian blood pressure pattern in essential hypertension: a comparative study. Cardiovasc Drugs Ther 1997; 11: 795-9.
76. Negrea S, Latea L, Bolboaca S. Effects of Valsartan and Nebivolol Treatment on Blood Pressure Variability in Hypertensive Patients. AMJ 2010; 4: 248-252.
77. Liu-DeRyke X, Levy PD, Parker D Jr, Coplin W, Rhoney DH. A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. Neurocrit Care 2013; 19: 41-7.
78. Zhang Y, Agnoletti D, Blacher J, Safar ME. Blood pressure variability in relation to autonomic nervous system dysregulation: the X-CELLENT study. Hypertens Res 2012; 35: 399-403.
79. Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 2011; 58: 155-60.
80. Ruddy M, Bialy GB, Malka ES. The effects of doxazosin on blood pressure variability in hypertensives. Am J Hypertens 2001; 14: 40A.
81. Scholze J, Bramlage P, Trenkwalder P, Kreutz R. Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother 2011; 12: 2771-9.
82. Zuern CS, Rizas KD, Eick C, et al. Effects of Renal Sympathetic Denervation on 24-hour Blood Pressure Variability. Front Physiol 2012; 3: 134
83. Pagonas N, Dimeo F, Bauer F, Seibert F, Kiziler F, Zidek W, Westhoff TH. The impact of aerobic exercise on blood pressure variability. J Hum Hypertens 2013; in press
84. Bregvadze T, Tseluyko V, Mishchuk N. Influence of treatment with olmesartan on ambulatory blood pressure monitoring parameters in patients with arterial hypertension. Georgian Med News. 2013; 225: 60-7.
85. Chen L, Jiang H, Hua Q, Yang HY, Zheng JT, Jin H, Jiao Y, Wang Y, Sun RH, Ke YN. The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension. Zhonghua Nei Ke Za Zhi 2013; 52: 749-52.
86. Frattola A, Parati G, Castiglioni P, Paleari F, Ulian L, Rovaris G, Mauri G, Di Rienzo M, Mancia G. Lacidipine and blood pressure variability in diabetic hypertensive patients. Hypertension 2000; 36: 622-8.
87. Bonaduce D, Canonico V, Petretta M, et al. Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, crossover study. Eur J Clin Pharmacol 1997; 53: 95-100.
88. Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension 2012; 59: 1132-8.
89. Ishikura K, Obara T, Kato T, et al. Associations between day-byday variability in blood pressure measured at home and antihypertensive drugs: the J-HOME-Morning study. Clin Exp Hypertens 2012; 34: 297-304.
90. Ushigome E, Fukui M, Hamaguchi M, et al Beneficial effect of calcium channel blockers on home blood pressure variability in the morning in patients with type 2 diabetes. J Diabetes Invest 2013; 4: 399-404.
91. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-80.
92. Höcht C, Bertera FM, Taira CA. Importance of blood pressure variability in the assessment of cardiovascular risk and benefits of antihypertensive therapy. Expert Rev Clin Pharmacol 2010; 3: 617-21.
93. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375: 906-15.
94. Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: a systematic review. Stroke 2011; 42: 2860-5.
95. Webb AJ, Fischer U, Rothwell PM. Effects of_-blocker selectivity on blood pressure variability and stroke: a systematic review. Neurology 2011; 77: 731-7.
96. Poirier L, Tobe S. Contemporary use of beta-blockers Clinical relevance of subclassification. Can J Cardiol 2014; in press.
97. Cahan A, Ben-Dov IZ, Bursztyn M. Association of heart rate with blood pressure variability: implications for blood pressure measurement. Am J Hypertens 2012; 25: 313-8.
98. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: Evidence from randomized controlled trials. J Am Soc Hypertens 2014; in press
99. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens 2012; 30: 1241-51.
100. [100] Diaz KM, Muntner P, Levitan EB, Brown MD, Babbitt DM, Shimbo D. The effects of weight loss and salt reduction on visit-tovisit blood pressure variability: results from a multicenter randomized controlled trial. J Hypertens. 2013; in press
101. [101] Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
102. [102] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.
103. [103] National Clinical Guideline Centre (UK), Hypertension: The ClinicalManagement of PrimaryHypertension in Adults: Update of Clinical Guidelines 18 and 34 [Internet], Royal College of Physicians, London, UK, 2011. Available at: www.nice.org.uk
104. [104] O’Brien E. Stabilizing blood pressure variability: a new therapeutic target in hypertension. Medicographia 2012; 34: 25-31.
105. [105] Redon J. The importance of 24-hour ambulatory blood pressure monitoring in patients at risk of cardiovascular events. High Blood Press Cardiovasc Prev 2013; 20: 13-8.